NCT07138885进行中（未招募）2 期
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2025年8月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR) by RECIST 1.1
研究概览
简要总结
The goal of this prospective Phase II clinical trial is to evaluate the efficacy and safety of QL1706-based combination therapy in patients with hepatocellular carcinoma (HCC) who have failed prior targeted-immunotherapy (e.g., anti-PD-1/PD-L1 + antiangiogenic therapy).
The main question is:
Can the combination of localized-regional therapy (e.g., HAIC/TACE) and systemic dual immunotherapy (QL1706) overcome resistance and improve outcomes in second-line HCC treatment?
Participants will:
- Receive QL1706 (a dual immune checkpoint inhibitor) combined with either:
Hepatic arterial infusion chemotherapy (HAIC)/transarterial chemoembolization (TACE), or Antiangiogenic targeted therapy. 2. Undergo regular imaging (e.g., MRI/CT) and biomarker assessments for efficacy monitoring. 3. Be evaluated for adverse events (AEs) and quality of life.
This study seeks to establish a novel therapeutic paradigm for HCC patients after targeted-immunotherapy failure, addressing the unmet need for evidence-based second-line strategies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Days 至 65 Days（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary Participation, Willingly signs the written informed consent form.
- •Aged 18-65 years (inclusive), any gender.
- •Histologically, cytologically, or clinically confirmed hepatocellular carcinoma (HCC) with disease progression after first-line targeted therapy combined with immunotherapy, or intolerable to first-line targeted-immunotherapy combination treatment.
- •No prior exposure to VEGF monoclonal antibodies, CTLA-4 inhibitors, or bispecific antibodies. For arm 1: No prior treatment with oxaliplatin or fluorouracil-based drugs.
- •Liver Function: Child-Pugh class A or class B (score ≤7), with no history of hepatic encephalopathy.
- •Performance Status: ECOG PS score 0 or
- •Life Expectancy ≥12 weeks.
- •Measurable Lesion: ≥1 measurable target lesion per RECIST v1.1 (not previously irradiated/localized; lesions in prior treatment areas are acceptable if progression is confirmed).
- •Preserved organ & bone marrow function (within 7 days before treatment; no blood products/growth factors within 14 days prior):
- •Neutrophil count (ANC) ≥1.5×10⁹/L
- •Platelets ≥75×10⁹/L
- •Hemoglobin ≥90 g/L
- •Albumin ≥28 g/L
- •ALT/AST/Alkaline phosphatase (AKP) ≤3×ULN
- •Total bilirubin (TBIL) ≤2×ULN
- •INR ≤2 or PT prolongation ≤6 sec above ULN
- •Urine protein <2+ (if ≥2+, 24-hour urine protein must be <1.0 g).
- •Viral Hepatitis Management
- •If HBsAg-positive: HBV DNA <2000 IU/mL or 10⁴ copies/mL, with ongoing antiviral therapy (entecavir/tenofovir disoproxil fumarate/tenofovir alafenamide/emtecavir).
- •HCV-infected patients with undetectable HCV RNA are considered HCV-negative.
- •Contraception
- •Fertile participants (male/female) must use reliable contraception (hormonal/barrier/abstinence) during and for ≥180 days post-treatment.
- •Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment.
排除标准
- •Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma.
- •Other active malignancies within 5 years prior to enrollment, except cured localized tumors (e.g., basal cell carcinoma, squamous cell skin cancer, superficial bladder cancer, in situ prostate/cervical/breast cancer).
- •History of or planned liver transplantation.
- •Clinically significant ascites requiring therapeutic paracentesis, uncontrolled pleural/pericardial effusion (asymptomatic minimal ascites on imaging allowed).
- •Known CNS metastases or leptomeningeal disease.
- •Tumor thrombus involving both main portal vein and superior mesenteric vein, or portal vein and inferior vena cava.
- •High-risk variceal bleeding:
- •Esophageal/gastric variceal bleeding within 6 months
- •High-grade varices on endoscopy within 3 months
- •Portal hypertension with bleeding risk (splenomegaly, active ulcers, occult blood+, or endoscopic "red signs").
- •Life-threatening hemorrhage within 3 months requiring transfusion/surgery/medical intervention.
- •Significant bleeding risk:
- •Hemoptysis/tumor bleeding within 2 weeks
- •Thromboembolism within 6 months
- •Therapeutic anticoagulation (except prophylactic LMWH) within 2 weeks
- •Antiplatelet therapy (aspirin >325 mg/day, clopidogrel >75 mg/day) within 10 days
- •Tumor invasion of major vessels/airways/mediastinum.
- •Severe cardiovascular disease:
- •Significant arrhythmias (requiring intervention), QTcF ≥450 ms (M)/470 ms (F)
- •ACS/heart failure/stroke/TIA within 6 months
- •NYHA class ≥II or LVEF <50%
- •Uncontrolled hypertension (≥160/100 mmHg despite ≥2 agents).
- •Abdominal fistula/GI perforation/abscess within 6 months.
- •Bowel obstruction/clinical signs of GI obstruction within 6 months.
- •Non-healing wounds, active ulcers, or untreated fractures.
- •Active autoimmune diseases or history of autoimmune diseases with potential recurrence (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism [patients with hypothyroidism controlled by hormone replacement therapy alone are not excluded]). Note: Patients with non-systemic skin conditions (e.g., vitiligo, psoriasis, alopecia), well-controlled type 1 diabetes on insulin, or childhood asthma with complete remission in adulthood requiring no intervention may be enrolled. Asthma patients requiring bronchodilator therapy are excluded.
- •Immunosuppressants (>10 mg/day prednisone equivalent) within 2 weeks.
- •Severe hypersensitivity to monoclonal antibodies.
- •Hepatic encephalopathy or CNS metastases.
- •Organ transplant history.
- •Symptomatic ascites requiring drainage within 3 months.
- •Uncontrolled hypertension (≥140/90 mmHg despite treatment).
- •Arterial/venous thrombosis within 6 months (stroke, DVT, PE).
- •Bleeding/thrombotic disorders (hemophilia, coagulopathy, thrombocytopenia).
- •Proteinuria ≥++ with 24-h urine protein >1.0 g.
- •Active infection (fever ≥38.5°C within 7 days or WBC >15×10⁹/L).
- •Interstitial lung disease (current or steroid-requiring history).
- •Active tuberculosis (confirmed by imaging/sputum/clinical assessment).
- •Immunodeficiency (HIV/syphilis).
- •Severe infection within 4 weeks (hospitalization required) or antibiotics within 2 weeks (prophylaxis allowed).
- •Recent treatments:
- •Liver surgery/HCC locoregional therapy within 4 weeks
- •Palliative bone radiotherapy within 2 weeks
- •Anti-HCC herbal medicine within 2 weeks
- •Unresolved toxicities (>Grade 1 per CTCAE v5.0, except alopecia).
- •Immunomodulators (interferons, interleukins) within 2 weeks.
- •Other investigational drugs within 4 weeks.
- •Allogeneic stem cell/organ transplant.
- •HBV-HCV coinfection.
- •Hypersensitivity to trial drug components/monoclonal antibodies/antiangiogenic agents.
- 另有 3 项未显示
研究组 & 干预措施
HAI-FOLFOX + bevacizumab + QL1706
Experimental
To evaluate the objective response rate (ORR) of HAI-FOLFOX + bevacizumab + QL1706 in patients with intermediate-advanced hepatocellular carcinoma (HCC) who developed resistance or recurrence after prior treatment with surgical resection/ablation/TACE combined with TKIs and/or PD-(L)1 inhibitors.
干预措施: HAI-FOLFOX + bevacizumab + QL1706 (Procedure)
TACE + bevacizumab + QL1706 + TAS-102
Experimental
To evaluate the objective response rate (ORR) of TACE + bevacizumab + TAS-102 + QL1706 in patients with intermediate-advanced HCC who developed resistance or recurrence after prior HAI-FOLFOX combined with TKIs and/or PD-(L)1 inhibitors.
干预措施: TACE + bevacizumab + TAS-102 + QL1706 (Procedure)
结局指标
主要结局
Objective response rate (ORR) by RECIST 1.1
时间窗: From date of first dose of study drug until disease progression (up to approximately 3 years)
ORR is defined as the percentage of participants who have best overall response (BOR) of complete response (CR) or partial response (PR) at the time of data cutoff as assessed by RECIST 1.1.
次要结局
- Objective response rate (ORR) by mRECIST(From date of first dose of study drug until disease progression (up to approximately 3 years))
- The disease control rate (DCR)(From date of first dose of study drug until disease progression, stable disease (up to approximately 3 years))
- The time to response (TTR)(From date of first dose of study drug to the date of first documentation of CR or PR (up to approximately 3 years))
- Duration of response (DOR) by RECIST 1.1 and mRECIST(From the first documentation of CR or PR to the first date of documentation of disease progression or death whichever occurs first (up to approximately 3 years))
- The progression-free survival time (PFS)(From date of first dose of study drug to the date of first documentation of disease progression or death (up to approximately 3 years))
- The median overall survival time (OS)(From the start date of the Treatment Phase until date of death from any cause (up to approximately 3 years))
- The progression-free survival rate (PFSR) by RECIST 1.1 and mRECIST(From date of first dose of study drug to the date of first documentation of disease progression or death, whichever occurs first (up to approximately 3 years))
- The overall survival rate (OSR)(From date of first dose of study drug to the date of documentation of death from any cause (up to approximately 3 years))
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(From the start date of the Treatment Phase until date of death from any cause (up to approximately 3 years))
- Exploratory outcome measure: The quality of life (QoL)(From date of first dose of study drug to the date of first documentation of disease progression within the liver or death (up to approximately 3 years))
研究者
Tian-Qi Zhang
Associate Professor, Associate Chief Physician
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT07049185Peking University Cancer Hospital & Institute35
招募中
2 期
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaHilar CholangiocarcinomaBile Duct CancerCholangiocarcinomaNCT07030140Jinbo Yue38
尚未招募
2 期
Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional TherapyHepatocellular CarcinomaNCT05975463HuiKai Li30
Unknown
2 期
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesNon-Small Cell Squamous Lung CancerBrain MetastasesNCT05207904Sun Yat-sen University41
尚未招募
2 期
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)NCT06714266Shandong Cancer Hospital and Institute30